Business
Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.
NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer (NMIBC, U.S. prevalence of ~600,000 patients, with ~62,000 newly diagnosed patients annually) Topline efficacy and safety Phase 2 data expected to be reported at the American Urological Association meeting (AUA), being held April 26-29, 2025 in Las Vegas NDV-01 has the potential to be a first-line therapy for NMIBC, presenting attractiv
About this update from Relmada Therapeutics, Inc.
[{"type":"image","alt":"Relmada Therapeutics","displaySize":"","headline":null,"caption":"Relmada Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":130,"height":33,"url":"https://media.zenfs.com/en/globenewswire.com/864e8ce076842deb8ff51dcb2351bb2e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ttP74diEks8HOrImNeTk.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTUzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/864e8ce076842deb8ff51dcb2351bb2e","width":130,"height":33}},"lazy":false},{"type":"text","content":"NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer (NMIBC, U.S. prevalence of ~600,000 patients, with ~62,000 newly diagnosed patients annually)","length":255,"tagName":"p"},{"type":"text","content":"Topline efficacy and safety Phase 2 data expected to be reported at the American Urological Association meeting (AUA), being held April 26-29, 2025 in Las Vegas","length":160,"tagName":"p"},{"type":"text","content":"NDV-01 has the potential to be a first-line therapy for NMIBC, presenting attractive clinical benefits for clinicians and patients","length":131,"tagName":"p"},{"type":"text","content":"CORAL GABLES, Fla., March 25, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced the completion of an exclusive licensing agreement with Trigone Pharma, Ltd. (Trigone) for NDV-01, a novel sustained-release intravesical formulation of gemcitabine and docetaxel (gem/doce) for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). The efficacy and safety of the NDV-01 are being evaluated in a Phase 2 study. First data are expected to be reported at the American Urological Association meeting (AUA), being held April 26-29, 2025 in Las Vegas.","length":708,"tagName":"p"},{"type":"text","content":"“We are delighted to add NDV-01 to our pipeline as we believe it represents an exceptional value-creation opportunity for Relmada and our investors. The drug development expertise of our Team provides flexibility to be opportunistic and consider programs that have the potential to be high-value assets and that can demonstrate proof-of-concept in the near-term, ...